Molecular signatures of basal cell carcinoma susceptibility and pathogenesis: A genomic approach

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 583-596

  Heller, Elizabeth Rose ^a   Gor, Ankit ^a   Wang, Dan ^b   Hu, Qiang ^b   Lucchese, Alberta ^c   Kanduc, Darja ^d   Katdare, Meena ^e,f,g   Liu, Song ^b   Sinha, Animesh A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f HAMPTON UNIVERSITY   (United States)

^g EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Basal cell carcinoma; Gene expression; Genetics; Microarray; Non melanoma; Pathogenesis; Skin cancer; Tumor

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER GENETICS; CANCER SUSCEPTIBILITY; CASE REPORT; CELL INTERACTION; CHROMOSOME 5; DISEASE DURATION; DOWN REGULATION; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN GENOME; HUMAN TISSUE; LIPID METABOLISM; MALE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RNA EXTRACTION; TUMOR BIOPSY; UPREGULATION;

AGED; AGED, 80 AND OVER; CARCINOGENESIS; CARCINOMA, BASAL CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; LIPID METABOLISM; MALE; PPAR GAMMA; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873616853     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1725     Document Type: Article

References (82)

1. Armstrong BK and Kricker A: Skin cancer. Dermatol Clin 13: 583-594, 1995.
2. Rubin AI, Chen EH and Ratner D: Basal-cell carcinoma. N Engl J Med 353: 2262-2269, 2005.
3. Sexton M, Jones DB and Maloney ME: Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 23: 1118-1126, 1990.
4. Diepgen TL and Mahler V: The epidemiology of skin cancer. Br J Dermatol 146 (Suppl. 61): S1-S6, 2002.
5. Reifenberger J, Wolter M, Knobbe CB, et al: Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152: 43-51, 2005.
6. Benjamin CL, Melnikova VO and Ananthaswamy HN: P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 624: 265-282, 2008.
7. De Zwaan SE and Haass NK: Genetics of basal cell carcinoma. Australas J Dermatol 51: 81-93, 2010.
8. Iwasaki JK, Srivastava D, Moy RL, Lin HJ and Kouba DJ: The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol 66: E167-E168, 2012.
9. Lacour JP: Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. Br J Dermatol 146 (Suppl 61): S17-S19, 2002.
10. Muller PA, Vousden KH and Norman JC: p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-218, 2011.
11. Gentleman RC, Carey VJ, Bates DM, et al: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80, 2004.
12. Wilson CL and Miller CJ: Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis. Bioinformatics 21: 3683-3685, 2005.
13. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3, 2004.
14. Benjamini Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 57: 289-300, 1995.
15. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998.
16. Huang da W, Sherman BT, Tan Q, et al: DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35: W169-W175, 2007.
17. Asplund A, Gry Bjorklund M, Sundquist C, et al: Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma. Br J Dermatol 158: 527-538, 2008.
18. Howell BG, Solish N, Lu C, et al: Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior. J Dermatol Sci 39: 39-51, 2005.
19. O'Driscoll L, McMorrow J, Doolan P, et al: Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Mol Cancer 5: 74, 2006.
20. Yu M, Zloty D, Cowan B, et al: Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol 128: 1797-1805, 2008.
21. Nijsten T, Geluyckens E, Colpaert C and Lambert J: Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol 32: 340-347, 2005.
22. Tachibana K, Yamasaki D, Ishimoto K and Doi T: The role of PPARs in cancer. PPAR Res 2008: 102737, 2008.
23. Reka AK, Goswami MT, Krishnapuram R, Standiford TJ and Keshamouni VG: Molecular cross-regulation between PPAR-gamma and other signaling pathways: implications for lung cancer therapy. Lung Cancer 72: 154-159, 2011.
24. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052, 1998.
25. Guan YF, Zhang YH, Breyer RM, Davis L and Breyer MD: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1: 330-339, 1999.
26. Mossner R, Schulz U, Kruger U, et al: Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 119: 576-582, 2002.
27. Petta E, Sotiropoulou-Bonikou G, Kourelis K, Melachrinou M and Bonikos DS: Differential expression and cross-talk of peroxisome proliferator-activated receptor gamma and retinoid-X receptor alpha in urothelial carcinomas of the bladder. J BUON 15: 740-745, 2010.
28. Pancione M, Forte N, Sabatino L, et al: Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 40: 714-725, 2009.
29. Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465-470, 1998.
30. Yao L, Liu F, Sun L, et al: Upregulation of PPARgamma in tissue with gastric carcinoma. Hybridoma (Larchmt) 29: 341-343, 2010.
31. Wang W, Wang R, Zhang Z, Li D and Yut Y: Enhanced PPAR-gamma expression may correlate with the development of Barrett's esophagus and esophageal adenocarcinoma. Oncol Res 19: 141-147, 2011.
32. Li M, Lee TW, Mok TS, Warner TD, Yim AP and Chen GG: Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 96: 760-774, 2005.
33. Boiteux G, Lascombe I, Roche E, et al: A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 124: 1820-1828, 2009.
34. Storch J and Thumser AE: Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 285: 32679-32683, 2010.
35. Wetmore C: Sonic hedgehog in normal and neoplastic proliferation: insight gained from human tumors and animal models. Curr Opin Genet Dev 13: 34-42, 2003.
36. Green DR and Kroemer G: Cytoplasmic functions of the tumour suppressor p53. Nature 458: 1127-1130, 2009.
37. Sun Y, Zeng XR, Wenger L, Firestein GS and Cheung HS: P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J Cell Biochem 92: 258-269, 2004.
38. Jung YS, Qian Y and Chen X: Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 22: 1003-1012, 2010.
39. Tanaka K, Iwamoto Y, Ito Y, et al: Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res 55: 2927-2935, 1995.
40. Tartaglia M and Gelb BD: Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci 1214: 99-121, 2010.
41. Dunn KL, Espino PS, Drobic B, He S and Davie JR: The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol 83: 1-14, 2005.
42. Yang D, Tao J, Li L, et al: RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma. Oncogene 30: 4590-600, 2011.
43. Mathiasen DP, Egebjerg C, Andersen SH, et al: Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 31: 390-401, 2012.
44. Shi XH, Liang ZY, Ren XY and Liu TH: Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther 16: 227-236, 2009.
45. Rauch J, Moran-Jones K, Albrecht V, et al: c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway. Cancer Res 71: 4664-4674, 2011.
46. Su E, Han X and Jiang G: The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia. Tumori 96: 659-666, 2010.
47. Chen CR, Kang Y, Siegel PM and Massague J: E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110: 19-32, 2002.
48. Jiang Y, Yim SH, Xu HD, et al: A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol 17: 470-477, 2011.
49. Polanowska J, Le Cam L, Orsetti B, et al: Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors. Genes Chromosomes Cancer 28: 126-130, 2000.
50. Van Haren R, Feldman D and Sinha AA: Systematic comparison of nonmelanoma skin cancer microarray datasets reveals lack of consensus genes. Br J Dermatol 161: 1278-1287, 2009.
51. Tanaka K, Iyama K, Kitaoka M, et al: Differential expression of alpha 1(IV), alpha 2(IV), alpha 5(IV) and alpha 6(IV) collagen chains in the basement membrane of basal cell carcinoma. Histochem J 29: 563-570, 1997.
52. Bishop DT, Demenais F, Iles MM, et al: Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41: 920-925, 2009.
53. Gerstenblith MR, Shi J and Landi MT: Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res 23: 587-606, 2010.
54. Gudbjartsson DF, Sulem P, Stacey SN, et al: ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 40: 886-891, 2008.
55. Han J, Kraft P, Nan H, et al: A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 4: e1000074, 2008.
56. Han J, Qureshi AA, Prescott J, et al: A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 129: 415-421, 2009.
57. Liboutet M, Portela M, Delestaing G, et al: MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J Invest Dermatol 126: 1510-1517, 2006.
58. Nan H, Kraft P, Hunter DJ and Han J: Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 125: 909-917, 2009.
59. Nan H, Xu M, Kraft P, et al: Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. Hum Mol Genet 20: 3718-3724 2011.
60. Rafnar T, Sulem P, Stacey SN, et al: Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41: 221-227, 2009.
61. Stacey SN, Gudbjartsson DF, Sulem P, et al: Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet 40: 1313-1318, 2008.
62. Stacey SN, Sulem P, Masson G, et al: New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 41: 909-914, 2009.
63. Wu C, Hu Z, He Z, et al: Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 43: 679-684, 2011.
64. Christensen GB, Baffoe-Bonnie AB, George A, et al: Genome-wide linkage analysis of 1, 233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. Prostate 70: 735-744, 2010.
65. Xu J, Dimitrov L, Chang BL, et al: A combined genomewide linkage scan of 1, 233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 77: 219-229, 2005.
66. Sun LD, Xiao FL, Li Y, et al: Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet 43: 690-694, 2011.
67. Beyer K, Nickel R, Freidhoff L, et al: Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. J Invest Dermatol 115: 906-908, 2000.
68. Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG and Montgomery GW: Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 130: 520-528, 2010.
69. Han J, Colditz GA, Samson LD and Hunter DJ: Polymorphisms in DNA double-strand break repair genes and skin cancer risk. Cancer Res 64: 3009-3013, 2004.
70. Sulem P, Gudbjartsson DF, Stacey SN, et al: Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 40: 835-837, 2008.
71. Sulem P, Gudbjartsson DF, Stacey SN, et al: Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet 39: 1443-1452, 2007.
72. Han J, Hankinson SE, Colditz GA and Hunter DJ: Genetic variation in XRCC1, sun exposure, and risk of skin cancer. Br J Cancer 91: 1604-1609, 2004.
73. Kang SY, Lee KG, Lee W, et al: Polymorphisms in the DNA repair gene XRCC1 associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population. Cancer Sci 98: 716-720, 2007.
74. Brown KM, Macgregor S, Montgomery GW, et al: Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 40: 838-840, 2008.
75. Smyth I, Narang MA, Evans T, et al: Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet 8: 291-297, 1999.
76. Fan Z, Li J, Du J, et al: A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. J Med Genet 45: 303-308, 2008.
77. Grachtchouk M, Mo R, Yu S, et al: Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet 24: 216-217, 2000.
78. Friedman E, Gejman PV, Martin GA and McCormick F: Non-sense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours. Nat Genet 5: 242-247, 1993.
79. Hahn H, Wicking C, Zaphiropoulous PG, et al: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85: 841-851, 1996.
80. Aszterbaum M, Epstein J, Oro A, et al: Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med 5: 1285-1291, 1999.
81. Svard J, Heby-Henricson K, Persson-Lek M, et al: Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev Cell 10: 187-197, 2006.
82. Ling G, Ahmadian A, Persson A, et al: PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 20: 7770-7778, 2001.